Live Breaking News & Updates on Editas medicine inc

Stay informed with the latest breaking news from Editas medicine inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Editas medicine inc and stay connected to the pulse of your community

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price […]

Los-angeles , California , United-states , Ohio , Gilmore-neil-oneill , Baisong-mei , Virtu-financial , Barclays , Citigroup , Los-angeles-capital-management , Jpmorgan-chase-co , Securities-exchange-commission

Critical Analysis: Editas Medicine (NASDAQ:EDIT) and CARGO Therapeutics (NASDAQ:CRGX)

CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Ratings This is a summary of […]

California , United-states , Cambridge , Cambridgeshire , United-kingdom , Massachusetts , Therapeutics-inc , Syncopation-life-sciences-inc , Editas-medicine-inc , Juno-therapeutics-inc , Gengine-inc

Crispr Therapeutics: Now Is The Time To Buy (NASDAQ:CRSP)

Crispr Therapeutics: Now Is The Time To Buy (NASDAQ:CRSP)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Intellia-therapeutics-inc , Editas-medicine-inc , Melinda-gates-foundation , Vertex-pharmaceuticals-incorporated , Centers-for-medicare , Medicaid-services , Vertex-pharmaceuticals , National-institute-of-health , Beam-therapeutics-inc , United-kingdom , Investor-relations

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 -- Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral...

United-states , Cambridge , Cambridgeshire , United-kingdom , American , Lindac-burkly , Broad-institute-cas , Harvard-university-cas , Editas-medicine-inc , Broad-institute , Exchange-commission

Editas Medicine (EDIT) to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline

Editas Medicine (EDIT) to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Lindac-burkly , Nasdaq , Meeting-of-the-american-society-gene , Editas-medicine-inc , Editas-medicine , Annual-meeting , American-society , Cell-therapy , Executive-vice-president

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Cambridge , Cambridgeshire , United-kingdom , American , Lindac-burkly , Editas-medicine-inc , Meeting-of-the-american-society-gene , Harvard-university-cas , Broad-institute-cas , Nasdaq

Genome Editing Market size is set to grow by USD 7.23 bn from 2024-2028,rapid technological advancements in genome editing boost the market- Technavio

/PRNewswire/ -- The global genome editing market size is estimated to grow by USD 7.23 bn from 2024-2028, according to Technavio. The market is estimated to...

United-kingdom , China , Germany , Canada , United-states , America , Jesse-maida , Intellia-therapeutics-inc , Perkinelmer-inc , Merck-kgaa , Horizon-discovery-ltd , Market-research-overview

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Consensus PT from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target […]

Baisong-mei , Gilmore-neil-oneill , Nasdaq , Investors-services , York-mellon-corp , Editas-medicine-inc , Barclays , Securities-exchange-commission , Citigroup , Jpmorgan-chase-co , Wells-fargo-company , Editas-medicine

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Average Target Price from Analysts

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month […]

Baisong-mei , Gilmore-neil-oneill , Russell-investments-group-ltd , Barclays , Editas-medicine-inc , Lazard-asset-management , Nasdaq , Covestor-ltd , Jpmorgan-chase-co , Citigroup , Editas-medicine-company-profile , Editas-medicine

Taysha Gene Therapies (NASDAQ:TSHA) vs. Editas Medicine (NASDAQ:EDIT) Head-To-Head Analysis

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation. Insider & Institutional Ownership 25.9% of […]

University-of-texas-southwestern-medical-center , Texas , United-states , Cambridge , Cambridgeshire , United-kingdom , Massachusetts , Dallas , Juno-therapeutics-inc , Allergan-pharmaceuticals-international , Editas-medicine-inc